Optimization of Cardiac Metabolism in Heart Failure

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2011 Sep 22

PMID 21933140

Citations 72

Authors

Tomohisa Nagoshi

Michihiro Yoshimura

Giuseppe M C Rosano

Gary D Lopaschuk

Seibu Mochizuki

Affiliations

Soon will be listed here.

Abstract

The derangement of the cardiac energy substrate metabolism plays a key role in the pathogenesis of heart failure. The utilization of non-carbohydrate substrates, such as fatty acids, is the predominant metabolic pathway in the normal heart, because this provides the highest energy yield per molecule of substrate metabolized. In contrast, glucose becomes an important preferential substrate for metabolism and ATP generation under specific pathological conditions, because it can provide greater efficiency in producing high energy products per oxygen consumed compared to fatty acids. Manipulations that shift energy substrate utilization away from fatty acids toward glucose can improve the cardiac function and slow the progression of heart failure. However, insulin resistance, which is highly prevalent in the heart failure population, impedes this adaptive metabolic shift. Therefore, the acceleration of the glucose metabolism, along with the restoration of insulin sensitivity, would be the ideal metabolic therapy for heart failure. This review discusses the therapeutic potential of modifying substrate utilization to optimize cardiac metabolism in heart failure.

Citing Articles

Identifying risk factors and constructing a predictive model for heart failure combined with intracardiac thrombus in non-compaction cardiomyopathy patients.

Dang P, Wang H, Huo X, Liang Z, Zhang Y Sci Rep. 2025; 15(1):2121.

PMID: 39814828 PMC: 11735604. DOI: 10.1038/s41598-025-85902-6.

Sex-dependent adaptations in heart mitochondria from transgenic mice overexpressing cytochrome b reductase-3.

Sanchez-Mendoza L, Gonzalez-Reyes J, Rodriguez-Lopez S, Calvo-Rubio M, Calero-Rodriguez P, de Cabo R Mitochondrion. 2025; 81:102004.

PMID: 39793940 PMC: 11875916. DOI: 10.1016/j.mito.2025.102004.

Ceramides as Biomarkers of Cardiovascular Diseases and Heart Failure.

Augusto Jr S, Suresh A, Tang W Curr Heart Fail Rep. 2024; 22(1):2.

PMID: 39560878 DOI: 10.1007/s11897-024-00689-3.

Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond.

Sun Q, Karwi Q, Wong N, Lopaschuk G Cardiovasc Res. 2024; 120(16):1996-2016.

PMID: 39453987 PMC: 11646102. DOI: 10.1093/cvr/cvae231.

Potential mechanisms of metabolic reprogramming induced by ischemia-reperfusion injury in diabetic myocardium.

Ma H, Zhao J, Zheng Y, Wang J, Anwar Y, He Y J Diabetes. 2024; 16(10):e70018.

PMID: 39450829 PMC: 11503499. DOI: 10.1111/1753-0407.70018.

References

Kim S, Abdellatif M, Koul S, Crystal G . Chronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathway. Am J Physiol Heart Circ Physiol. 2008; 295(1):H130-5. PMC: 2494754. DOI: 10.1152/ajpheart.00298.2008. View

Rupp H, Vetter R . Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure. Br J Pharmacol. 2001; 131(8):1748-56. PMC: 1572500. DOI: 10.1038/sj.bjp.0703741. View

Paolisso G, Gambardella A, Galzerano D, DAmore A, Rubino P, Verza M . Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism. 1994; 43(2):174-9. DOI: 10.1016/0026-0495(94)90241-0. View

Stanley W, Recchia F, Lopaschuk G . Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005; 85(3):1093-129. DOI: 10.1152/physrev.00006.2004. View

Nikolaidis L, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L . Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004; 110(8):955-61. DOI: 10.1161/01.CIR.0000139339.85840.DD. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G . Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006; 27(8):942-8. DOI: 10.1093/eurheartj/ehi816. View

Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A . The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109(1):121-30. PMC: 150824. DOI: 10.1172/JCI14080. View

Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N . Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. 2010; 120(5):1506-14. PMC: 2860916. DOI: 10.1172/JCI40096. View

10.

Kitamura K, Kangawa K, Matsuo H, Uyeda K . Phosphorylation of myocardial fructose-6-phosphate,2-kinase: fructose-2,6-bisphosphatase by cAMP-dependent protein kinase and protein kinase C. Activation by phosphorylation and amino acid sequences of the phosphorylation sites. J Biol Chem. 1988; 263(32):16796-801. View

11.

Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R . Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005; 115(8):2108-18. PMC: 1180541. DOI: 10.1172/JCI24682. View

12.

Lawlor M, Alessi D . PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci. 2001; 114(Pt 16):2903-10. DOI: 10.1242/jcs.114.16.2903. View

13.

Freel E, Tsorlalis I, Lewsey J, Latini R, Maggioni A, Solomon S . Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. Heart. 2009; 95(23):1920-4. DOI: 10.1136/hrt.2009.173344. View

14.

Boudina S, Sena S, ONeill B, Tathireddy P, Young M, Abel E . Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation. 2005; 112(17):2686-95. DOI: 10.1161/CIRCULATIONAHA.105.554360. View

15.

Hasenfuss G, Maier L, Hermann H, Luers C, Hunlich M, Zeitz O . Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium. Circulation. 2002; 105(2):194-9. DOI: 10.1161/hc0202.102238. View

16.

Matsui T, Li L, del MonteF , Fukui Y, Franke T, Hajjar R . Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999; 100(23):2373-9. DOI: 10.1161/01.cir.100.23.2373. View

17.

Matsui T, Li L, Wu J, Cook S, Nagoshi T, Picard M . Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002; 277(25):22896-901. DOI: 10.1074/jbc.M200347200. View

18.

Depre C, Vanoverschelde J, Taegtmeyer H . Glucose for the heart. Circulation. 1999; 99(4):578-88. DOI: 10.1161/01.cir.99.4.578. View

19.

Pound K, Sorokina N, Ballal K, Berkich D, Fasano M, LaNoue K . Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res. 2009; 104(6):805-12. PMC: 2908318. DOI: 10.1161/CIRCRESAHA.108.189951. View

20.

Brazil D, Hemmings B . Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci. 2001; 26(11):657-64. DOI: 10.1016/s0968-0004(01)01958-2. View